Epidemiological Differences of COVID-19 Over the World

被引:6
作者
Sayed, Abida [1 ]
Challa, Krishna Teja [1 ]
Arja, Sateesh [2 ]
机构
[1] Avalon Univ, Dept Med & Res, Sch Med, Willemstad, Neth Antilles
[2] Avalon Univ, Sch Med, Med Clin Skills, Willemstad, Neth Antilles
关键词
coronavirus; covid-19; bcg vaccine; bacillus calmette guerin vaccine; BCG; INFECTION; MORTALITY; SCAR;
D O I
10.7759/cureus.10316
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Coronavirus disease 2019 (COVID-19), originally, from Wuhan, China, has now spread to most countries across the globe and devastated global healthcare systems. The impact of this disease has, however, shown baffling variations in prevalence in different regions of the world. The aim of this short review is to identify differential national COVID-19 prevalence of COVID-19, as well as to suggest these epidemiological differences. Methods A review of studies was conducted using PubMed and Google Scholar search engines. Search tactics were centered on COVID-19 ("COVID-19" AND "coronavirus") and BCG vaccination ("BCG vaccination" OR "Bacillus Calmette-Guerin" OR "vaccine") Results It is found that national prevalence differences may be linked with BCG childhood immunization history. A statistically insignificant difference was observed in COVID-19 prevalence when comparing countries with a BGC policy and countries without it (P > 0.05). This inconclusivity suggests the influence of confounders in this study. Conclusions National differences in COVID-19 cases can be attributable to immunologic regulations, such as BCG vaccination protocols. Caution should be taken in establishing a correlation between COVID-19 prevalence and BCG vaccination, partly due to the weak quality of statistical data on COVID-19 related to poor testing rates in countries with BCG vaccination policy. Nonetheless, the analysis of the epidemiological aspects of COVID-19 will shed light on future efforts towards effective control and prevention.
引用
收藏
页数:7
相关论文
共 27 条
[1]  
[Anonymous], 2020, DAILY MORTALITY RATE
[2]  
[Anonymous], 2020, COR DIS 2019 COVID 1
[3]  
[Anonymous], 2020, MEDRXIV, DOI DOI 10.1101/2020.04.10.20060905
[4]  
[Anonymous], 2020, Coronavirus disease (COVID-19): outbreak update
[5]  
[Anonymous], 2024, Coronavirus Incubation Period
[6]   BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity [J].
Arts, Rob J. W. ;
Moorlag, Simone J. C. F. M. ;
Novakovic, Boris ;
Li, Yang ;
Wang, Shuang-Yin ;
Oosting, Marije ;
Kumar, Vinod ;
Xavier, Ramnik J. ;
Wijmenga, Cisca ;
Joosten, Leo A. B. ;
Reusken, Chantal B. E. M. ;
Benn, Christine S. ;
Aaby, Peter ;
Koopmans, Marion P. ;
Stunnenberg, Hendrik G. ;
van Crevel, Reinout ;
Netea, Mihai G. .
CELL HOST & MICROBE, 2018, 23 (01) :89-+
[7]  
Berg M.K., 2020, SCI ADV, DOI 10.1101/2020.04.05.20054163
[8]   Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial [J].
Biering-Sorensen, Sofie ;
Aaby, Peter ;
Lund, Najaaraq ;
Monteiro, Ivan ;
Jensen, Kristoffer Jarlov ;
Eriksen, Helle Brander ;
Schaltz-Buchholzer, Frederik ;
Jorgensen, Anne Sofie Pinstrup ;
Rodrigues, Amabelia ;
Fisker, Ane Baerent ;
Benn, Christine Stabell .
CLINICAL INFECTIOUS DISEASES, 2017, 65 (07) :1183-1190
[9]  
Escobar Luis E, 2020, Proc Natl Acad Sci U S A, V117, P17720, DOI [10.1073/pnas.2008410117, 10.1101/2020.05.05.20091975]
[10]   BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa -: A non-specific beneficial effect of BCG? [J].
Garly, ML ;
Martins, CL ;
Balé, C ;
Baldé, MA ;
Hedegaard, KL ;
Gustafson, P ;
Lisse, IM ;
Whittle, HC ;
Aaby, P .
VACCINE, 2003, 21 (21-22) :2782-2790